|Day's Range||1.76 - 1.80|
|52 Week Range||1.46 - 8.75|
|PE Ratio (TTM)||-1.21|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
On May 8, 2017, Aralez Pharmaceuticals Inc. (ARLZ) announced financial results for the first quarter of 2017 and provided a business update. The $26.0 million of revenue consisted of $6.7 million in net product revenues, which are derived from the product portfolio acquired from the acquisition of Tribute along with net product revenues from YOSPRALA® and Fibricor®. Other revenues of $19.3 million were comprised of $15.6 million in revenues from the acquisitions of Toprol-XL® and Zontivity® and Vimovo® royalties of $3.7 million.
On a per-share basis, the Milton, Ontario-based company said it had a loss of 42 cents. The specialty pharmaceutical company posted revenue of $26 million in the period. Aralez Pharmaceuticals expects ...
Fourth-quarter earnings and guidance for 2017 were not what the doctor ordered.